TJP1 and metabolic disease: C.B intervention significantly ameliorated gut microbiota imbalance in obese mice and alleviated obesity-related metabolic disorders by upregulating the expression of tight junction proteins (ZO-1 and occludin), attenuating endotoxemia and systemic inflammation and reducing microbial-derived BCAA production.